| 22.47 -0.59 (-2.56%) | 08-10 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.78 | 1-year : | 32.44 |
| Resists | First : | 23.78 | Second : | 27.78 |
| Pivot price | 22.2  |
|||
| Supports | First : | 21.82 | Second : | 20.61 |
| MAs | MA(5) : | 22.46 | MA(20) : | 21.94 |
| MA(100) : | 12.4 |
MA(250) : | 9.71 |
|
| MACD | MACD : | 1.2  |
Signal : | 1.6 |
| %K %D | K(14,3) : | 58.1 |
D(3) : | 58.4 |
| RSI | RSI(14): 71.2 | |||
| 52-week | High : | 28 | Low : | 3.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SGTX ] has closed below upper band by 40.1%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 22.52 - 22.63 | 22.63 - 22.72 |
| Low: | 22.16 - 22.31 | 22.31 - 22.44 |
| Close: | 22.26 - 22.49 | 22.49 - 22.68 |
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Mon, 14 Aug 2023
Lilly Completes Acquisition of Sigilon Therapeutics | Eli Lilly and Company - Investors | Eli Lilly and Company
Thu, 29 Jun 2023
Moderna (MRNA) Billionaire Afeyan Adds to Fortune as Sigilon Stock (SGTX) Soars - Bloomberg
Thu, 29 Jun 2023
Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today? - InvestorPlace
Thu, 29 Jun 2023
Sigilon Therapeutics Shares Are Shooting Higher Today - What's Going On - Yahoo Finance
Thu, 29 Jun 2023
Eli Lilly to Acquire Sigilon Therapeutics - Investopedia
Thu, 29 Jun 2023
Sigilon Therapeutics’ stock soars 550% after Eli Lilly agrees to acquire company - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 8.6 (%) |
| Held by Institutions | 54.3 (%) |
| Shares Short | 8 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -14.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.97 |
| Profit Margin | -171.3 % |
| Operating Margin | -174.7 % |
| Return on Assets (ttm) | -23.7 % |
| Return on Equity (ttm) | -76.4 % |
| Qtrly Rev. Growth | 104.5 % |
| Gross Profit (p.s.) | -9.88 |
| Sales Per Share | 7.05 |
| EBITDA (p.s.) | -11.84 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -1.52 |
| PEG Ratio | 0 |
| Price to Book value | 2.04 |
| Price to Sales | 3.18 |
| Price to Cash Flow | -1.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|